Clene to Present at Emerging Growth Conference, October 23, 2025.

Clene Inc. will present at the Emerging Growth Conference on October 23, 2025, at 3:10 p.m. ET. The virtual presentation will cover a corporate update and will be available on Clene's website and the Emerging Growth YouTube Channel. Clene is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases.

Clene Inc. (Nasdaq: CLNN), a clinical-stage biopharmaceutical company, will present a corporate update at the Emerging Growth Conference on October 23, 2025, at 3:10 p.m. ET. The virtual presentation will cover the company's progress in developing treatments for neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis. The presentation will be available on Clene's website and the Emerging Growth YouTube Channel.

Clene Inc. and its wholly-owned subsidiary Clene Nanomedicine Inc. focus on improving mitochondrial health and protecting neuronal function. Their lead candidate, CNM-Au8®, is an investigational first-in-class therapy that targets mitochondrial function and the NAD pathway while reducing oxidative stress. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland.

The Emerging Growth Conference is an effective platform for public companies to present their new products and services to the investment community. The conference will be conducted through video webcasts and will take place in the Eastern time zone. The audience includes potentially tens of thousands of individual and institutional investors, as well as investment advisors and analysts.

Clene Inc. has a strong pipeline of clinical trials and has shown promising results in its Phase 2/3 studies. The company has scheduled key FDA meetings to discuss its ALS treatment program and plans to submit a New Drug Application (NDA) in Q4 2025 for potential accelerated approval. In its recent financial results, the company reported a cash position of $7.3 million as of June 30, 2025, with additional funds raised post-quarter, providing runway into Q1 2026.

For more information about Clene Inc. and its subsidiaries, visit their website at www.clene.com or follow them on X (formerly Twitter) and LinkedIn.